DelveInsight's 'Primary Myelofibrosis - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Primary Myelofibrosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Study Period: 2017-2030
The DelveInsight Primary Myelofibrosis epidemiology report gives a thorough understanding of the Primary Myelofibrosis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Primary Myelofibrosis in the US, Europe, and Japan. The report covers the detailed information of the Primary Myelofibrosis epidemiology scenario in seven major countries (US, EU5, and Japan).
The Primary Myelofibrosis epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Primary Myelofibrosis epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Primary Myelofibrosis epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
The Primary Myelofibrosis epidemiology covered in the report provides historical as well as forecasted Primary Myelofibrosis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
The DelveInsight Primary Myelofibrosis report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
1. Key Insights
2. Executive Summary of Primary Myelofibrosis
3. Primary Myelofibrosis: Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Primary Myelofibrosis Epidemiology Scenario in the 7MM (2017- 2030)
5.4. United States Epidemiology
5.4.1. Primary Myelofibrosis Epidemiology Scenario in the United States (2017- 2030)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Primary Myelofibrosis Epidemiology Scenario in Germany (2017- 2030)
5.5.2. France Epidemiology
5.5.2.1. Primary Myelofibrosis Epidemiology Scenario in France (2017- 2030)
5.5.3. Italy Epidemiology
5.5.3.1. Primary Myelofibrosis Epidemiology Scenario in Italy (2017- 2030)
5.5.4. Spain Epidemiology
5.5.4.1. Primary Myelofibrosis Epidemiology Scenario in Spain (2017- 2030)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Primary Myelofibrosis Epidemiology Scenario in the United Kingdom (2017-2030)
5.6. Japan Epidemiology
5.6.1. Primary Myelofibrosis Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Primary Myelofibrosis Treatment and Management
6.2. Primary Myelofibrosis Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
*The table of contents is not exhaustive; will be provided in the final report
Table 1 Primary Myelofibrosis Epidemiology in 7MM (2017-2030)
Table 2 Primary Myelofibrosis Diagnosed and Treatable Cases in 7MM (2017-2030)
Table 3 Primary Myelofibrosis Epidemiology in the United States (2017-2030)
Table 4 Primary Myelofibrosis Diagnosed and Treatable Cases in the United States (2017-2030)
Table 5 Primary Myelofibrosis Epidemiology in Germany (2017-2030)
Table 6 Primary Myelofibrosis Diagnosed and Treatable Cases in Germany (2017-2030)
Table 7 Primary Myelofibrosis Epidemiology in France (2017-2030)
Table 8 Primary Myelofibrosis Diagnosed and Treatable Cases in France (2017-2030)
Table 9 Primary Myelofibrosis Epidemiology in Italy (2017-2030)
Table 10 Primary Myelofibrosis Diagnosed and Treatable Cases in Italy (2017-2030)
Table 11 Primary Myelofibrosis Epidemiology in Spain (2017-2030)
Table 12 Primary Myelofibrosis Diagnosed and Treatable Cases in Spain (2017-2030)
Table 13 Primary Myelofibrosis Epidemiology in the United Kingdom (2017-2030)
Table 14 Primary Myelofibrosis Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Table 15 Primary Myelofibrosis Epidemiology in Japan (2017-2030)
Table 16 Primary Myelofibrosis Diagnosed and Treatable Cases in Japan (2017-2030)
Figure 1 Primary Myelofibrosis Epidemiology in 7MM (2017-2030)
Figure 2 Primary Myelofibrosis Diagnosed and Treatable Cases in 7MM (2017-2030)
Figure 3 Primary Myelofibrosis Epidemiology in the United States (2017-2030)
Figure 4 Primary Myelofibrosis Diagnosed and Treatable Cases in the United States (2017-2030)
Figure 5 Primary Myelofibrosis Epidemiology in Germany (2017-2030)
Figure 6 Primary Myelofibrosis Diagnosed and Treatable Cases in Germany (2017-2030)
Figure 7 Primary Myelofibrosis Epidemiology in France (2017-2030)
Figure 8 Primary Myelofibrosis Diagnosed and Treatable Cases in France (2017-2030)
Figure 9 Primary Myelofibrosis Epidemiology in Italy (2017-2030)
Figure 10 Primary Myelofibrosis Diagnosed and Treatable Cases in Italy (2017-2030)
Figure 11 Primary Myelofibrosis Epidemiology in Spain (2017-2030)
Figure 12 Primary Myelofibrosis Diagnosed and Treatable Cases in Spain (2017-2030)
Figure 13 Primary Myelofibrosis Epidemiology in the United Kingdom (2017-2030)
Figure 14 Primary Myelofibrosis Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Figure 15 Primary Myelofibrosis Epidemiology in Japan (2017-2030)
Figure 16 Primary Myelofibrosis Diagnosed and Treatable Cases in Japan (2017-2030)
*The table of contents is not exhaustive; will be provided in the final report
